All podcasts

Creating Targeted Antibodies in Single Cells

Antibodies are one line of adaptive immune response, responding to new antigens that may represent threats. Some types of immunotherapy exploit antibodies that can target specific cell types, like those that emerge in certain cancers. However, developing antibodies for specific targets can be challenging for a variety of technical reasons. Dr. Liang Schweizer from HiFiBio discusses her company's approach of creating custom antibodies in single cells that speed the drug discovery process.

Aug 20, 2022 by Dr. Kevin Folta in Talking Biotech

Apple podcasts link Google podcasts link Spotify podcasts link

Immunotherapies represent a powerful suite of treatments that co-opt the immune system to target deleterious cellular conditions. They have been effective with a series of cancers and other disorders. The problem is that development of new antibodies can be challenging for several technical reasons, but also because no two people are alike. Dr. Liang Schweizer of HiFiBio describes how her company is using single-cells and microfluidics to identify new antibodies that may be mobilized against discrete cellular targets, as well as what they have learned about heterogeneity between patients and how to identify specific biomarkers that could guide application of the most effective treatments.


Get your whole lab on the same page today.

Learn more